All In Biotech

NDA 214962 · Cycle

Tascenso Odt

Fingolimod Lauryl Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 9, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

218

64 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2026.

TASCENSO ODT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. TASCENSO ODT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Mechanism: Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod phosphate is a sphingosine 1-phosphate receptor modulator and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown but may involve reduction of lymphocyte migration into the central nervous system.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TASCENSO ODT · FINGOLIMOD LAURYL SULFATE EQ 0.25MG BASE · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription
  • TASCENSO ODT · FINGOLIMOD LAURYL SULFATE EQ 0.5MG BASE · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fingolimod Lauryl" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heart rate decreased28
  • fatigue25
  • headache21
  • dizziness15
  • somnolence12
  • multiple sclerosis relapse11
  • gait disturbance8
  • nausea8
  • asthenia7
  • drug ineffective7
  • hypertension7
  • hospitalisation6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202373
202488
202544
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tascenso ODT (Fingolimod Lauryl Sulfate)

2024 spending

$1.9M

Beneficiaries

30

171 claims

Per beneficiary

$64,639

$338.49 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$480,969
2024$1,939,183

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Cycle

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.